

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Dexxon Holdings Ltd.</u>  (Last) (First) (Middle) 1 DEXCEL STREET  (Street) OR AKIVA L3 3060000  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/08/2016	3. Issuer Name and Ticker or Trading Symbol <u>Arbutus Biopharma Corp [ ABUS ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares, no par value	16,013,540	I	See footnote. <sup>(1)(2)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>Dexxon Holdings Ltd.</u>  (Last) (First) (Middle) 1 DEXCEL STREET  (Street) OR AKIVA L3 3060000  (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Oren Dan</u>  (Last) (First) (Middle) 1 DEXCEL STREET  (Street) OR AKIVA L3 3060000  (City) (State) (Zip)		
--	--	--

**Explanation of Responses:**

1. Dexxon Holdings Ltd. ("Dexxon") and its sole director, Dan Oren (together with Dexxon, the "Reporting Persons") are filing this Form 3 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the 16,013,540 common shares (the "Common Shares") of Arbutus Biopharma Corporation (the "Issuer") held by Roivant Sciences Ltd. ("Roivant") by virtue of governance arrangements in Roivant's bye-laws. The Reporting Persons do not directly own any Common Shares. Dexxon is a shareholder of Roivant and is one of the holders of the Override Right (as defined below). Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Dan Oren is ultimately the sole shareholder of Dexxon. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant.

2. The filing of this statement shall not be deemed an admission that either Dexxon or Mr. Oren is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Effective July 8, 2016, Dr. Andrew Lo was appointed to the board of directors of Roivant (the "Board"). Dr. Lo is an "independent director" within the meaning of that term under Roivant's bye-laws. As of the appointment of the independent director, Dexxon, voting unanimously, with two other major shareholders of Roivant, has the right to override certain decisions of the Board under Roivant's bye-laws, including with respect to dispositions of Common Shares (the "Override Right"). The Reporting Persons are filing this Form 3 because they may be accordingly deemed to have "dispositive power" and, therefore, beneficial ownership, over the Common Shares owned directly by Roivant due to the Override Right.

/s/ Dexxon Holdings Ltd. by 07/13/2016  
Dan Oren, Director

/s/ Dan Oren 07/13/2016

\*\* Signature of Reporting Person Date

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**